Princess Cruises' Sphere Class ships, Sun Princess and Star Princess, have been named the #1 Mega Cruise Ships in the Condé Nast Traveler 2026 Readers' Choice Awards. This recognition highlights their innovative design, exceptional dining, entertainment, and personalized service, with Sun Princess winning for the third consecutive year and Star Princess earning top honors in her first year of eligibility. These ships offer unique experiences including stunning venues like The Dome and the Princess Arena, diverse culinary options, and exclusive retreats like The Sanctuary Collection. The awards reflect strong customer approval and reinforce Princess Cruises' position as a leader in the cruise industry.
Princess Cruises' recognition as #1 Mega Cruise Ship offers context for cruise industry interest. For readers following Consumer Cyclical stocks, here is Pluang's market snapshot as of Oct 07, 2026 01:21 WIB: 73 of 112 US stocks rose and 39 fell. Norwegian Cruise Line Holdings Ltd (NCLH) rose 4.24% to USD 15.50 with 100% buy orders and a typical hold time of 68 days. Royal Caribbean Cruises Ltd (RCL) rose 4.18% to USD 286.52 with 100% buy orders and a typical hold time of 84 days. MakeMyTrip Ltd (MMYT) fell 4.20% to USD 43.11 with a typical hold time of 12 days.
Constellation Brands reported earnings per share of $3.74, surpassing analyst estimates of $3.55, and revenue of $2.63 billion, exceeding the $2.54 billion forecast. The company saw a 5% increase in beer sales and a 17% rise in wine and spirits sales...
Tilray Brands will announce its fiscal Q1 2027 earnings on October 8, with analysts forecasting a loss of $0.16-$0.19 per share on revenues around $265-$268 million, marking about 26% growth from last year. Investors will focus on cannabis and bevera...
On October 6, 2026, five notable stocks surged between 20.9% and 52.7%, driven by various positive developments. Apimeds Pharmaceuticals rose 52.7% after its subsidiary signed a blockchain contract, while Option Care Health gained 32.7% following a $...
On October 6, five notable stocks saw significant declines, with losses ranging from 17.5% to 50.1%. ArriVent BioPharma's shares plunged 46.9% after its lung cancer treatment failed to meet the primary endpoint in a Phase 3 trial. Armada Acquisition ...
Evercore ISI raised its price target for Marvell Technology to $433 from $275, maintaining an Outperform rating. This follows Marvell's optimistic revenue projections, expecting $20 billion by fiscal 2028 and $70-$90 billion by fiscal 2031, driven by...
